摘要
目的探讨多西他赛对乳腺癌患者糖代谢的影响。方法 124例经术后病理证实的女性乳腺癌患者术后均接受含多西他赛方案化疗,化疗前均已排除血糖异常及糖尿病,观察每周期化疗前后血糖及糖化血红蛋白变化。结果全部124例患者均按计划完成6周期化疗。化疗后有11例(8.87%)空腹血糖升高,24例(19.35%)糖耐量减低;其中诊断为2型糖尿病者8例(6.45%),一过性血糖增高5例(4.03%)。结论乳腺癌接受含多西他赛方案化疗后可能引起血糖增高、糖耐量减低,甚至2型糖尿病,化疗期间应密切监测血糖及糖化血红蛋白水平,及时干预治疗。
Objective To evaluate the effect of docetaxel on the glycometabolism of patients with breast cancer. Methods One hundred and twenty-four patients with breast cancer treated with operation received the docetaxel combined chemotherapy after operation, and the pathoglycemia and diabetes mellitus were evacuated, the blood glu- cose and glycosylated hemoglobin levels were detected before and after chemotherapy. Results All the 124 patients finished the docetaxel combined chemotherapy. After the chemotherapy, the high fasting glucose level was observed in the 11 patients （8.87%）, the low glucose tolerance in the 24 patients （ 19.4% ） ; type 2 diabetes mellitus was observed in the 8 patients （6.45%） , the transient increased blood sugar in the 5 patients （4.03%）. Conclusion Docetaxel could increase the blood glucose level, decrease the glucose tolerance, and maybe induce type 2 diabetes mellitus, the timely diagnosis and treatment should be given.
出处
《肿瘤基础与临床》
2015年第1期19-21,共3页
journal of basic and clinical oncology
关键词
乳腺癌
化疗
血糖
多西他赛
breast cancer
chemotherapy
diabete
docetaxel
作者简介
罗丽琼（1976-），女，硕士，主治医师，主要从事肿瘤综合治疗工作。E—mail：llq2017@163．com
